Stenotrophomonas Maltophilia in Lower Respiratory Tract Infections

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2015 Feb 6

PMID 25653948

Citations 16

Authors

Kiran Chawla

Shashidhar Vishwanath

Ashu Gupta

Affiliations

Soon will be listed here.

Abstract

Background: Stenotrophomonas maltophilia infection is gaining importance as an important cause of nosocomial pneumonia due to its characteristic inherent resistance to many broad- spectrum antibiotics. In this study we evaluated the demographic, clinical and microbiological profile of patients with lower respiratory tract infection due to Stenotrophomonas maltophilia.

Materials And Methods: A retrospective analysis of 33 patients diagnosed with Stenotrophomonas maltophilia lower respiratory tract infections during a period of two years from 2012 - 2013 was done.

Results: The predominant predisposing factor observed was mechanical ventilation in 17(51.5%) cases. Fluoroquinolones were the most effective antibiotic (26;78.8%) followed by trimethoprim-sulfamethoxazole (24;72.7%). Among the 19 patients treated with proper antibiotic, 13(68.4%) showed clinical improvement. Among the 14 patients who did not receive appropriate antibiotic for Stenotrophomonas maltophilia infection, 8(57.1%) showed improvement. Two (6%) had blood culture positive for Stenotrophomonas maltophilia. Mortality rate was 21.2%.

Conclusion: Stenotrophomonas maltophilia is emerging as an important nosocomial pathogen with increased risk in patients on mechanical ventilation in ICU. Empiric therapy should include agents active against S.maltophilia such as newer flouroquinolones and trimethoprim-sulfamethoxazole.

Citing Articles

Functional metagenomics highlights varied infection states with dynamics of pathogens and antibiotic resistance in lower respiratory tract infections.

Shamim U, Yadav A, Maurya R, Devi P, Kumari P, Kanika Heliyon. 2024; 10(19):e38380.

PMID: 39416816 PMC: 11481616. DOI: 10.1016/j.heliyon.2024.e38380.

Integrated large-scale metagenome assembly and multi-kingdom network analyses identify sex differences in the human nasal microbiome.

Ju Y, Zhang Z, Liu M, Lin S, Sun Q, Song Z Genome Biol. 2024; 25(1):257.

PMID: 39380016 PMC: 11463039. DOI: 10.1186/s13059-024-03389-2.

The respiratory tract microbiome, the pathogen load, and clinical interventions define severity of bacterial pneumonia.

Perez-Cobas A, Ginevra C, Rusniok C, Jarraud S, Buchrieser C Cell Rep Med. 2023; 4(9):101167.

PMID: 37633274 PMC: 10518590. DOI: 10.1016/j.xcrm.2023.101167.

Global prevalence and antibiotic resistance in clinical isolates of : a systematic review and meta-analysis.

Banar M, Sattari-Maraji A, Bayatinejad G, Ebrahimi E, Jabalameli L, Beigverdi R Front Med (Lausanne). 2023; 10:1163439.

PMID: 37215718 PMC: 10196134. DOI: 10.3389/fmed.2023.1163439.

Infection Trends, Susceptibility Pattern, and Treatment Options for Infections in Trauma Patients: A Retrospective Study.

Srivastava S, Singh P, Sharad N, Kiro V, Malhotra R, Mathur P J Lab Physicians. 2023; 15(1):106-109.

PMID: 37064968 PMC: 10104700. DOI: 10.1055/s-0042-1757413.

References

Looney W, Narita M, Muhlemann K . Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009; 9(5):312-23. DOI: 10.1016/S1473-3099(09)70083-0. View

Brooke J . Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012; 25(1):2-41. PMC: 3255966. DOI: 10.1128/CMR.00019-11. View

Betriu C, Sanchez A, Palau M, Gomez M, Picazo J . Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother. 2001; 48(1):152-4. DOI: 10.1093/jac/48.1.152. View

Falagas M, Valkimadi P, Huang Y, Matthaiou D, Hsueh P . Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother. 2008; 62(5):889-94. DOI: 10.1093/jac/dkn301. View

Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K . A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994; 38(3):624-7. PMC: 284510. DOI: 10.1128/AAC.38.3.624. View

SANYAL S, Mokaddas E . The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999; 11(1):28-33. DOI: 10.1179/joc.1999.11.1.28. View

Kwa A, Low J, Lim T, Leow P, Kurup A, Tam V . Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008; 37(10):826-30. View

Kassel T, Ryan L, Li A . Computed tomography features of Stenotrophomonas maltophilia pneumonia in patients with neutropenic fever: report of two cases. Multidiscip Respir Med. 2013; 8(1):14. PMC: 3626614. DOI: 10.1186/2049-6958-8-14. View

Neela V, Rankouhi S, van Belkum A, Goering R, Awang R . Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim-sulfamethoxazole resistance. Int J Infect Dis. 2012; 16(8):e603-7. DOI: 10.1016/j.ijid.2012.04.004. View

10.

Toleman M, Bennett P, Bennett D, Jones R, Walsh T . Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis. 2007; 13(4):559-65. PMC: 2725981. DOI: 10.3201/eid1304.061378. View

11.

Gautam V, Ray P, Vandamme P, Chatterjee S, Das A, Sharma K . Identification of lysine positive non-fermenting gram negative bacilli (Stenotrophomonas maltophilia and Burkholderia cepacia complex). Indian J Med Microbiol. 2009; 27(2):128-33. DOI: 10.4103/0255-0857.49425. View

12.

Denton M, Kerr K . Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998; 11(1):57-80. PMC: 121376. DOI: 10.1128/CMR.11.1.57. View